FDA Asks For Input On Therapeutic Equivalence
Comments On TE Codes And Patents Could Lead To 'Orange Book' Changes
The FDA wants to know if the second letter in its product equivalence ratings system is helpful and whether changes could make the information more user-friendly.
You may also be interested in...
Commissioner says agency will modernize drug patent reference manual this year and consider potential changes to Orange Book administration policy. However, any transformative moves could trigger a court challenge.
Six months after submission deadline, about one-third of one-time marketing status reports have been reviewed, agency says.
US agency is seeking feedback from interested stakeholders about administrative steps it can take to better promote generic competition; July 18 meeting will involve only presentations from the public.